J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Australians aged in their 30s and 40s are experiencing unprecedented and in some cases world-leading rates of 10 different ...

Australians in their 30s and 40s are being diagnosed with cancer at unprecedented rates, with at least 10 types of the ...

A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating ...

The review introduces the molecular subtypes of breast cancer and outlines how altered amino acid metabolism supports tumor ...